BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Delocamten readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Delocamten\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06122779-597@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Delocamten: Phase 2 readout est. (NCT06122779)
DESCRIPTION:Delocamten\, phase 2\, Heart Failure.\nStudy: Study to Evaluate
  Safety\, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participan
 ts With Heart Failure With Preserved Ejection Fraction (HFpEF)\nEstimated 
 primary completion: 14 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/delocamten#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06122779
URL:https://assetmemo.bio/drug/delocamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226817-597@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Delocamten: Phase 1 readout est. (NCT07226817)
DESCRIPTION:Delocamten\, phase 1.\nStudy: A Study to Assess the Relative Bi
 oavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy A
 dult Participants\nEstimated primary completion: 17 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/delocamten#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07226817
URL:https://assetmemo.bio/drug/delocamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
